BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, May 23, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Sep. 18, 2024

View Archived Issues
epitomee capsule

Epitomee swallows FDA clearance for weight loss capsule

Epitomee Ltd. happily swallowed the news of U.S. FDA clearance for its capsule for weight management, an ingestible medical device for adults who are overweight or obese. Designed for use along with diet and exercise, the capsule expands in the stomach to create a feeling of fullness that lasts up to six hours. Read More
Global market charts

Medtronic, Philips invest in med-tech companies with an eye to acquire

Strategics tend to invest in med-tech companies they are looking to acquire or could be acquired. Furthermore, companies like Medtronic plc and Royal Philips NV, which have venture arms, will continue to invest even through challenging times. Read More
Chatbot icon made with binary code.

Opportunities, hazards await with the use of AI in device design

Artificial intelligence is beginning to make its way into the world of medical device design, but Gregg Van Citters, senior consultant at Medicept, told BioWorld that there are both opportunities and tripwires on the road ahead. Read More
Australia flag with microscope, test tubes

Australia’s HTA consultation wraps up with 50 recommendations

Australia’s Health Department has released the final report of the Health Technology Assessment (HTA) Review that makes 50 recommendations for improving access to new health technologies while tackling inequity, simplifying HTA processes and making it easier for consumers and clinicians to participate. Read More
Science and medicine icons with head made of computer code

HHS announces LEAP in Health IT awards

The U.S. Department of Health and Human Services reported the winners of the Leading Edge Acceleration Projects in Health Information Technology program, with a couple of key areas of interest. Read More
Rebound arrows

Q2 sees med-tech financings rise 16.5% as sector builds momentum

The med-tech sector maintained its momentum in the second quarter, with total financings climbing 16.5% to $7.47 billion, compared to $6.41 billion in Q1. Read More

Appointments and advancements for September 18, 2024

New hires and promotions in the med-tech industry, including: 23andme Holdings, Parse Biosciences, True Digital Surgery. Read More

Financings for September 18, 2024

Med-tech firms raising money in public or private financings, including: Novostia. Read More

In the clinic for September 18, 2024

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Guardant, Implantica, Life Spine. Read More

Other news to note for September 18, 2024

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Activcell, Avery Telehealth, Beacon Biosignals, Biocardia, BWXT Medical, Colibri, Deroyal, Inhearing, Intricon, Jingha Medical, Kajeet, Laurentis, Lucid, Melling Medical, Pavemed, Progressive Medical, Quest Diagnostics, Sentara Health Plans, Surgibox, Thermology, Viromed Medical. Read More

Regulatory actions for September 18, 2024

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Elekta, Venus Concept, Visibly. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 22, 2026.
  • Acid alpha-glucosidase molecular structure isolated on black

    ‘Detargeted’ targeted gene therapy improves activity in Pompe

    BioWorld
    A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 19, 2026
  • Nxera Pharma prepares and tests new GPR17 antagonists

    BioWorld Science
    Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
  • Genescience presents STAT6 degrader for atopic dermatitis

    BioWorld Science
    Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing